Cardio Diagnostics Holdings Inc CDIO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-11-23 |
| Shares Out. | 2,960,000 |
| Website | cdio.ai ↗ |
| Phone | 18004831140 |
| Employees | 17 |
| Revenue | $5,360 |
| Gross Profit | $5,360 |
| Net Income | -$1.5M |
| Free Cash Flow | -$5.8M |
| Total Assets | $7.9M |
| Total Liabilities | $499,780 |
| Equity | $7.4M |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Cardio Diagnostics Holdings Inc is a publicly traded company under the ticker symbol CDIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2025-10-01)